Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4433MR)

This product GTTS-WQ4433MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4433MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10106MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ953MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ8484MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ9166MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ15619MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ4603MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ11600MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ12321MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW